NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $154.46 +2.55 (+1.68 %) (As of 11/18/2018 01:07 PM ET)Previous Close$154.46Today's Range$145.51 - $156.4652-Week Range$126.50 - $278.62Volume510,759 shsAverage Volume981,630 shsMarket Capitalization$3.28 billionP/E Ratio25.12Dividend YieldN/ABeta1.52 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California. Receive LGND News and Ratings via Email Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND Previous Symbol CUSIP53220K50 Webwww.ligand.com Phone858-550-7500 Debt Debt-to-Equity Ratio0.86 Current Ratio2.20 Quick Ratio2.19 Price-To-Earnings Trailing P/E Ratio25.12 Forward P/E Ratio26.14 P/E Growth1.31 Sales & Book Value Annual Sales$141.10 million Price / Sales23.26 Cash Flow$3.7701 per share Price / Cash40.97 Book Value$32.91 per share Price / Book4.69 Profitability EPS (Most Recent Fiscal Year)$2.57 Net Income$12.55 million Net Margins73.78% Return on Equity26.17% Return on Assets10.68% Miscellaneous Employees39 Outstanding Shares21,250,000Market Cap$3.28 billion OptionableOptionable Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Inc. (NASDAQ:LGND) issued its earnings results on Thursday, November, 8th. The biotechnology company reported $1.32 EPS for the quarter, beating the Zacks' consensus estimate of $1.03 by $0.29. The biotechnology company earned $45.66 million during the quarter, compared to analysts' expectations of $41.99 million. Ligand Pharmaceuticals had a net margin of 73.78% and a return on equity of 26.17%. The company's quarterly revenue was up 36.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.69 earnings per share. View Ligand Pharmaceuticals' Earnings History. When is Ligand Pharmaceuticals' next earnings date? Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Ligand Pharmaceuticals. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $6.52-6.52 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.37. The company issued revenue guidance of $240-240 million, compared to the consensus revenue estimate of $234.8 million. What price target have analysts set for LGND? 7 brokerages have issued 12 month price objectives for Ligand Pharmaceuticals' stock. Their predictions range from $105.00 to $300.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $235.00 in the next twelve months. This suggests a possible upside of 52.1% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals. What is the consensus analysts' recommendation for Ligand Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals. What are Wall Street analysts saying about Ligand Pharmaceuticals stock? Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock: 1. According to Zacks Investment Research, "Ligand reported encouraging third-quarter results, beating estimates on both counts. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, Ligand’s internal pipeline has several candidates in development that could generate future licensing opportunities. Ligand is acquiring other technology platforms to reduce dependence on Captisol formulation. Shares of Ligand have significantly outperformed the industry this year so far. The company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Both the drugs have shown encouraging growth with blockbuster potential. However, any setback related to either of these products could have a substantial impact." (11/15/2018) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $281 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 178 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (11/5/2018) Has Ligand Pharmaceuticals been receiving favorable news coverage? Media coverage about LGND stock has been trending neutral recently, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next few days. Are investors shorting Ligand Pharmaceuticals? Ligand Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 5,582,948 shares, an increase of 36.6% from the October 15th total of 4,087,344 shares. Based on an average daily trading volume, of 757,557 shares, the days-to-cover ratio is presently 7.4 days. Currently, 27.0% of the company's stock are short sold. View Ligand Pharmaceuticals' Current Options Chain. Who are some of Ligand Pharmaceuticals' key competitors? Some companies that are related to Ligand Pharmaceuticals include Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), Alkermes (ALKS) and SAGE Therapeutics (SAGE). Who are Ligand Pharmaceuticals' key executives? Ligand Pharmaceuticals' management team includes the folowing people: Mr. John L. Higgins, CEO & Exec. Director (Age 48)Mr. Matthew W. Foehr, Pres & COO (Age 45)Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 43)Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)Mr. Todd Pettingill, Director of Corp. Devel. Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.86%), William Blair Investment Management LLC (4.88%), Janus Henderson Group PLC (4.27%), Renaissance Technologies LLC (3.57%), Conestoga Capital Advisors LLC (2.68%) and FMR LLC (2.54%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals. Which institutional investors are selling Ligand Pharmaceuticals stock? LGND stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Glenmede Trust Co. NA, William Blair Investment Management LLC, Victory Capital Management Inc., Rice Hall James & Associates LLC, First Light Asset Management LLC, Man Group plc and Russell Investments Group Ltd.. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals. Which institutional investors are buying Ligand Pharmaceuticals stock? LGND stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, BlackRock Inc., Conestoga Capital Advisors LLC, Matarin Capital Management LLC, Canada Pension Plan Investment Board, Mackenzie Financial Corp and Putnam Investments LLC. View Insider Buying and Selling for Ligand Pharmaceuticals. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $154.46. How big of a company is Ligand Pharmaceuticals? Ligand Pharmaceuticals has a market capitalization of $3.28 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe. What is Ligand Pharmaceuticals' official website? The official website for Ligand Pharmaceuticals is http://www.ligand.com. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected] MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 402 (Vote Outperform)Underperform Votes: 249 (Vote Underperform)Total Votes: 651MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/18/2018 by MarketBeat.com StaffFeatured Article: What is a stock split?